Search
ID

Rintis Noviyanti

Senior Research Fellow

Qualification:

  • B.Sc(Hons) (University of Indonesia)
  • Postgraduate Diploma (University of Melbourne)
  • Ph.D (University of Melbourne)

Awards and Grants:

1. BioVentures for Global Health (BVGH)/FIT2/WIPO Sabbatical Fellowships, Feb 2018
2. Asia-Pacific Malaria Elimination Network, Aug 2017
3. Australia-APEC Women in Research Fellowship, Oct 2015
4. Australia Alumni Grant Scheme, Oct 2015
5. Collaborative Development Award, British High Commission, Sep 2013
6. iVax Travel Fellowships, New York Academy of Sciences and ISGlobal, May 2013
7. Malaria Transmission Consortium, UNICEF and BMGF, Nov 2012
8. Asia Pacific Malaria Elimination Network (APMEN), Sep 2011
9. Scientific Program Indonesia Netherlands (SPIN) Postdoctoral Grant, Sep 2008
10. Endeavour Postdoctoral Research Fellowships, Sep 2007
11. WHO Re-Entry Grant, Aug 2005
12. L'Oreal-UNESCO for Women in Science, Jul 2004
13. Travel Award to Microarray Workshop in Thailand, Jun 2003
14. Travel Award to Malaria Transfection Workshop in India, Apr 2002
15. Australia Development Scholarships for Postgraduate studies, Jun 1996

Publications

  1. Genomic analysis of a pre-elimination Malaysian Plasmodium vivax population reveals selective pressures and changing transmission dynamics.
    Nat Commun. 2018 Jul 3;9(1):2585. doi: 10.1038/s41467-018-04965-4.
    PubMed
  2. Quantifying primaquine effectiveness and improving adherence: a round table discussion of the APMEN Vivax Working Group.
    Malar J. 2018 Jun 20;17(1):241. doi: 10.1186/s12936-018-2380-8.
    PubMed
  3. Two clusters of Plasmodium knowlesi cases in a malaria elimination area, Sabang Municipality, Aceh, Indonesia.
    Malar J. 2018 May 2;17(1):186. doi: 10.1186/s12936-018-2334-1.
    PubMed
  4. The Plasmodium falciparum transcriptome in severe malaria reveals altered expression of genes involved in important processes including surface antigen-encoding var genes.
    PLoS Biol. 2018 Mar 12;16(3):e2004328. doi: 10.1371/journal.pbio.2004328. eCollection 2018 Mar.
    PubMed
  5. Therapeutic Response to Dihydroartemisinin-Piperaquine for P. falciparum and P. vivax Nine Years after Its Introduction in Southern Papua, Indonesia.
    Am J Trop Med Hyg. 2018 Mar;98(3):677-682. doi: 10.4269/ajtmh.17-0662. Epub 2018 Jan 11.
    PubMed
  6. Passively versus Actively Detected Malaria: Similar Genetic Diversity but Different Complexity of Infection.
    Am J Trop Med Hyg. 2017 Dec;97(6):1788-1796. doi: 10.4269/ajtmh.17-0364. Epub 2017 Aug 31.
    PubMed
  7. Plasmodium falciparum and Plasmodium vivax Demonstrate Contrasting Chloroquine Resistance Reversal Phenotypes.
    Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00355-17. doi: 10.1128/AAC.00355-17. Print 2017 Aug.
    PubMed
  8. A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance.
    Nat Commun. 2017 May 24;8:15159. doi: 10.1038/ncomms15159.
    PubMed
  9. Genetic micro-epidemiology of malaria in Papua Indonesia: Extensive P. vivax diversity and a distinct subpopulation of asymptomatic P. falciparum infections.
    PLoS One. 2017 May 12;12(5):e0177445. doi: 10.1371/journal.pone.0177445. eCollection 2017.
    PubMed
  10. Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group.
    Malar J. 2017 Apr 5;16(1):141. doi: 10.1186/s12936-017-1784-1.
    PubMed
  11. VivaxGEN: An open access platform for comparative analysis of short tandem repeat genotyping data in Plasmodium vivax populations.
    PLoS Negl Trop Dis. 2017 Mar 31;11(3):e0005465. doi: 10.1371/journal.pntd.0005465. eCollection 2017 Mar.
    PubMed
  12. Placental weight ratio affects placental mRNA expression of insulin-like growth factor-I and long isoform of the leptin receptor in Plasmodium falciparuminfected pregnant women.
    Asia Pac J Clin Nutr. 2016 Dec;25(Suppl 1):S75-S82.
    PubMed
  13. Submicroscopic and Asymptomatic Plasmodium Parasitaemia Associated with Significant Risk of Anaemia in Papua, Indonesia.
    PLoS One. 2016 Oct 27;11(10):e0165340. doi: 10.1371/journal.pone.0165340. eCollection 2016.
    PubMed
  14. A Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitor with Improved Drug-like Properties for Treatment and Prevention of Malaria.
    ACS Infect Dis. 2016 Dec 9;2(12):945-957. Epub 2016 Oct 4.
    PubMed
  15. Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose-Efficacy Modeling.
    PLoS Med. 2016 Oct 4;13(10):e1002138. doi: 10.1371/journal.pmed.1002138. eCollection 2016 Oct.
    PubMed
  16. Asymptomatic Vivax and Falciparum Parasitaemia with Helminth Co-Infection: Major Risk Factors for Anaemia in Early Life.
    PLoS One. 2016 Aug 9;11(8):e0160917. doi: 10.1371/journal.pone.0160917. eCollection 2016.
    PubMed
  17. Genomic analysis of local variation and recent evolution in Plasmodium vivax.
    Nat Genet. 2016 Aug;48(8):959-64. doi: 10.1038/ng.3599. Epub 2016 Jun 27.
    PubMed
  18. Characterization of blood dendritic and regulatory T cells in asymptomatic adults with sub-microscopic Plasmodium falciparum or Plasmodium vivax infection.
    Malar J. 2016 Jun 21;15:328. doi: 10.1186/s12936-016-1382-7.
    PubMed
  19. Corrigendum: A novel multiple-stage antimalarial agent that inhibits protein synthesis.
    Nature. 2016 Sep 1;537(7618):122. doi: 10.1038/nature18280. Epub 2016 May 25.
    PubMed
  20. Differences in PfEMP1s recognized by antibodies from patients with uncomplicated or severe malaria.
    Malar J. 2016 May 5;15(1):258. doi: 10.1186/s12936-016-1296-4.
    PubMed
  21. Analysis of ex vivo drug response data of Plasmodium clinical isolates: the pros and cons of different computer programs and online platforms.
    Malar J. 2016 Mar 2;15(1):137. doi: 10.1186/s12936-016-1173-1.
    PubMed
  22. Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia.
    BMC Med. 2015 Dec 11;13(1):294. doi: 10.1186/s12916-015-0535-9.
    PubMed
  23. Expression of Plasmodium vivax crt-o Is Related to Parasite Stage but Not Ex Vivo Chloroquine Susceptibility.
    Antimicrob Agents Chemother. 2015 Nov 2;60(1):361-7. doi: 10.1128/AAC.02207-15.
    PubMed
  24. Quantification of Plasmodium ex vivo drug susceptibility by flow cytometry.
    Malar J. 2015 Oct 24;14(1):417. doi: 10.1186/s12936-015-0940-8.
    PubMed
  25. Potent Ex Vivo Activity of Naphthoquine and Methylene Blue against Drug-Resistant Clinical Isolates of Plasmodium falciparum and Plasmodium vivax.
    Antimicrob Agents Chemother. 2015 Oct;59(10):6117-24. doi: 10.1128/AAC.00874-15. Epub 2015 Jul 20.
    PubMed
  26. Contrasting ex vivo efficacies of "reversed chloroquine" compounds in chloroquine-resistant Plasmodium falciparum and P. vivax isolates.
    Antimicrob Agents Chemother. 2015 Sep;59(9):5721-6. doi: 10.1128/AAC.01048-15. Epub 2015 Jul 6.
    PubMed
  27. A novel multiple-stage antimalarial agent that inhibits protein synthesis.
    Nature. 2015 Jun 18;522(7556):315-20. doi: 10.1038/nature14451.
    PubMed
  28. Preserved dendritic cell HLA-DR expression and reduced regulatory T cell activation in asymptomatic Plasmodium falciparum and P. vivax infection.
    Infect Immun. 2015 Jun 1. pii: IAI.00226-15.
    PubMed
  29. Contrasting Transmission Dynamics of Co-endemic Plasmodium vivax and P. falciparum: Implications for Malaria Control and Elimination.
    PLoS Negl Trop Dis. 2015 May 7;9(5):e0003739. doi: 10.1371/journal.pntd.0003739. eCollection 2015 May.
    PubMed
  30. G6PD Deficiency at Sumba in Eastern Indonesia Is Prevalent, Diverse and Severe: Implications for Primaquine Therapy against Relapsing Vivax Malaria.
    PLoS Negl Trop Dis. 2015 Mar 6;9(3):e0003602. doi: 10.1371/journal.pntd.0003602. eCollection 2015 Mar.
    PubMed
  31. The clinical and public health problem of relapse despite primaquine therapy: case review of repeated relapses of Plasmodium vivax acquired in Papua New Guinea.
    Malar J. 2014 Dec 12;13(1):488. doi: 10.1186/1475-2875-13-488.
    PubMed
  32. Platelet activation determines angiopoietin-1 and VEGF levels in malaria: implications for their use as biomarkers.
    PLoS One. 2013 Jun 3;8(6):e64850. doi: 10.1371/journal.pone.0064850. Print 2014.
    PubMed
  33. Quinolone-3-diarylethers: a new class of antimalarial drug.
    Sci Transl Med. 2013 Mar 20;5(177):177ra37. doi: 10.1126/scitranslmed.3005029.
    PubMed
  34. Effective preparation of Plasmodium vivax field isolates for high-throughput whole genome sequencing.
    PLoS One. 2013;8(1):e53160. doi: 10.1371/journal.pone.0053160. Epub 2013 Jan 4.
    PubMed
  35. Transcribed var genes associated with placental malaria in Malawian women.
    Infect Immun. 2006 Aug;74(8):4875-83.
    PubMed
  36. Malaria in Wanokaka and Loli sub-districts, West Sumba District, East Nusa Tenggara Province, Indonesia.
    Am J Trop Med Hyg. 2006 May;74(5):733-7.
    PubMed
  37. Broad analysis reveals a consistent pattern of var gene transcription in Plasmodium falciparum repeatedly selected for a defined adhesion phenotype.
    Mol Microbiol. 2005 May;56(3):774-88.
    PubMed
  38. Phenotypic switching and var gene transcription in Plasmodium falciparum.
    Adv Exp Med Biol. 2003;531:149-59.
    PubMed
  39. Transcription of multiple var genes by individual, trophozoite-stage Plasmodium falciparum cells expressing a chondroitin sulphate A binding phenotype.
    Mol Microbiol. 2002 Mar;43(5):1285-93.
    PubMed
  40. Multiple var gene transcripts are expressed in Plasmodium falciparum infected erythrocytes selected for adhesion.
    Mol Biochem Parasitol. 2001 May;114(2):227-37.
    PubMed